News / Korea / yonhap_finance
Shinhan Securities Trims Alteogen Price Target Following Clinical Trial Setback
Health Technology · Biotechnology · yonhap_finance · 2026-09-08
196170
Shinhan Securities lowered its target price for Alteogen to 520,000 KRW after a drug candidate in its Novartis licensing deal failed a Phase 3 trial.
What Happened
Price Target Adjustment: Shinhan Securities has lowered its target price for Alteogen from 540,000 KRW to 520,000 KRW, representing a 3.7% decrease. This adjustment follows the failure of 'Del-desiran,' one of the candidates in the licensing agreement with Novartis, to meet its primary endpoint in a Phase 3 clinical trial.
Contractual Impact: Analysts clarified that the clinical failure does not affect the overall value or terms of the existing 4.4 trillion KRW licensing deal with Novartis. While the number of confirmed subcutaneous (SC) conversion candidates has decreased from three to two, the core agreement remains intact.
Future Outlook: Alteogen continues to advance other promising candidates such as 'Del-zota' and 'Del-brax.' The brokerage firm maintains a 'Buy' rating, citing the potential for SC development across a broader pipeline, including antibody-drug conjugates (ADCs) and bispecific antibodies.
Market Sentiment: The revision is viewed as a technical adjustment to valuation rather than a fundamental issue. Alteogen remains a top pick within the sector, with analysts expressing confidence in the company's long-term development pipeline.
Read original
More in Health Technology
Health Technology · cnyes · 2026-09-09
Taiwanese pharmaceutical firm健喬 (4114-TW) reported a 49.88% year-on-year revenue increase for August, driven by strong sales in oncology and cardiovascular drugs.
4114
Health Technology · cnbc · 2026-09-08
Novartis shares dropped following a failed cardiovascular trial, weighing on the broader biotech sector, while Boeing reported a monthly decline in aircraft deliveries.
@CL.1, US10Y, .SPX, .IXIC, NVS, .DJI, AMGN, BA, NVS, LLY, XBI, @LCO26X, ABBV, GILD, NVDA, CHWY, SIG
Health Technology · economic_daily · 2026-09-08
Joyo Pharmaceutical announced a 50% year-over-year revenue increase for August, driven by strong sales in oncology, cardiovascular, and women's health products.
4114
Latest in Korea
Finance · yonhap_finance · 2026-09-09
Hana Bank has introduced a new service allowing retirement account holders to invest directly in retail government bonds, offering tax deferral and compound interest benefits.
Finance · yonhap_finance · 2026-09-09
The Korea Asset Management Corporation (KAMCO) has appointed Kim Kyung-jae, a former executive at Shinhan Securities, to lead its public development division.
Consumer Non-Durables · yonhap_finance · 2026-09-09
The Ministry of Agriculture, Food and Rural Affairs held a roadshow in Seoul to connect agri-food companies with global investors and mentors.
Electronic Technology · yonhap_finance · 2026-09-09
South Korean firms reported record-breaking revenue growth and operating margins in Q2, driven by a semiconductor boom, with broad improvements across sectors.
005930